

S134
Abstracts / Journal of Clinical Virology 82S (2016) S1–S142
CD27+, CD45RA
−
, CD45RO+, PD1
−
, CD57
−
). Expansion rate of func-
tional T cells measured by ELISPOT IFN-gamma response was in
range 8
×
to 120
×
for individual CMV antigens. In the next step,
we shall determine cytolytic response against peptide pulsed or
virus infected targets and allogeneic reactivity of antiviral T cells
expanded in different media. The results will be shown at themeet-
ing.
The work was supported by grant NV15-34498A from AZV,
Czech Republic.
http://dx.doi.org/10.1016/j.jcv.2016.08.268Abstract no: 145
Presentation at ESCV 2016: Poster 229
False-negative parvovirus B 19 serology in
pregnancy. Do we need PCR testing to detect or
exclude infection?
Barlinn Regine
1 ,∗
, H. Rollag
2, L. Trogstad
1,
P. Magnus
3, K. Vainio
1, S. Dudman
11
Division for Infection Control and Environmental
Health, Norwegian Institute of Public Health, Oslo,
Norway
2
Department of Medical Microbiology, Oslo
University Hospital, Norway
3
Division for Health Data and Digitalization,
Norwegian Institute of Public Health, Oslo, Norway
Aim:
The aim of the study was to investigate the parvovirus
B19 (B19) seroprevalence, new infection and vertical transmission
during pregnancy.
Material and methods:
Serum samples and questionnaires
from 1349 randomly selected pregnant women were included.
The samples were randomly selected from a Norwegian Mother
and Child Cohort Study (MoBa) that includes 114,000 children and
95,000 mothers recruited from all over Norway from 1999 to 2008.
Sera collected around week 17–18 (sample K1) were analysed for
B19 IgM and IgG using an enzyme linked immunosorbent assay
(Virion/Serion, Würzburg). All samples with IgG positive and IgM
negative results in K1 were classified as immune and no further
tests were done. IgG and IgM negative samples in K1 or samples
with an IgG equivocal result or IgM equivocal or positive result
were also analysed for B19 IgG and IgMon the sample taken at birth
(sample K2). Mothers with a seroconversion or with IgM equivocal
or positive results in K1 or K2 or with IgG equivocal results in K1
or K2 were tested with an in-house real-time B19 PCR. In addition,
corresponding umbilical cord blood samples were also analysed
with B19 PCR.
Results:
Mean age at delivery was 30.4 years and 40.2% was 29
year or younger. Mean gestational age at delivery was 39.7 weeks
and 47.1% was nulliparous. Of the 1349 women 61.7% were B19
IgG positive and IgM negative and 36% were both IgG and IgM neg-
ative. Among the initially seronegative women 6,8% seroconverted.
However, 2,3%had amore inconclusive serological profile including
either IgM or IgG equivocal results or IgM positive in K1and/or K2.
K1 and K2 samples from these 31 women with inconclusive sero-
logical profile and from the 33 women who seroconverted were
subjected to B19 PCR. Sixteen (51.6%) with inconclusive serological
profile and eighteen (54.6%) of those who seroconverted had virus
detectable by PCR either in K1 or K2 or both. Vertical infection was
seen in ten (15.6%) of these 64 children. Among the 16 women with
inconclusive serological profiles and a positive B19 PCR at week 17-
18, seven women were still seronegative also with an alternative
B19 IgG assay (Biotrin, Dublin) in the second sample taken at birth
(K2).
Conclusion:
In this cohort of pregnant women a high incidence
(2.5%) of viremic parvovirus B 19 infections was recorded, result-
ing in 26.5% of the children becoming infected. In almost half of
the women with an inconclusive serological profile combined with
positive PCR in K1, IgG was negative at birth (K2). In pregnancy
parvovirus B19 PCR is thus recommended since serology is often
not sufficient to detect or exclude infection.
http://dx.doi.org/10.1016/j.jcv.2016.08.269Abstract no: 226
Presentation at ESCV 2016: Poster 230
Human cytomegalovirus (HCMV) genotyping in
congenital infection
F. Ferreira
∗
, M.J. Chasqueira, P. Paixão
NOVA Medical School/Faculdade de Ciências
Médicas, Portugal
Background:
Human cytomegalovirus (HCMV) is the main con-
genital infection agent, affecting about 0.2–2.2% of all newborns.
This pathogen exhibits extensive genetic variabilitymainly in struc-
tural genes encoding envelope glycoproteins. The most relevant is
theHCMV glycoprotein B (gB), encoded by theUL55 gene, an impor-
tant target of the immune system of the human host. On the basis
of sequence variation of this gene, the virus can be classified at least
into 4 gB genotypes (types 1–4).
Objectives:
The aim of this study was to determine the
genotypes for UL55, present on samples from congenital and/or
perinatal infection cases in Portugal.
Study design:
HCMV gB genotyping was performed on 36
HCMV-positive urine samples and 20 amniotic fluid (LA) sam-
ples, collected from 2009 to 2016, by real time PCR. To confirm
the results, sequencing techniques (Sanger and Next-Generation
Sequencing) were performed.
Results:
35 urine samples could be assigned a gB genotype, in
29 was detected a single genotype (13 gB1; 7 gB2; 6 gB4; 3 gB3),
and in 6 mixed (>1) genotypes. Of the 19 LA samples, 17 had a sin-
gle genotype (5 gB1; 5 gB2; 5 gB3; 2 gB4), and in 2 were detected
mixed genotypes. No amplification was obtained in the other 2
samples (1 urine and 1 LA). Sequencing techniques did not confirm
the presence of mixed infections.
Conclusions:
gB1 seems to be the most common genotype in
congenital infection in Portugal, consistent with that described in
the literature. Also we corroborate the notion that all genotypes
can be involved in this type of infection. Mixed infections should
be subjected to further analysis, given the apparent contradiction
between PCR and sequencing results.
http://dx.doi.org/10.1016/j.jcv.2016.08.270Abstract no: 36
Presentation at ESCV 2016: Poster 231
Practical experience in laboratory diagnosis of
congenital CMV infection over a period of 8
years in Slovakia
K. Kollárová
∗
, D. Huˇcková
Medirex Inc, Canada
Primary and/or secondary cytomegalovirus infection of
pregnant women can lead to congenital (cCMV) or peri-/postnatal
infection. Serological screening of women before or during preg-
nancy for CMV specific antibodies is not usually performed in